SFI
PHAS

Susquehanna Fundamental Investments’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Susquehanna Fundamental Investments’s Portfolio PHAS Stock Details PHAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-15,232
Closed -$53K – 1831
2021
Q1 		$53K Sell
15,232
-32,738
-68% -$133K ﹤0.01% 1495
2020
Q4 		$161K Sell
47,970
-10,732
-18% -$38.4K ﹤0.01% 1386
2020
Q3 		$206K Buy
+58,702
New +$237K 0.01% 1187

Other funds holding PHAS

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Susquehanna Fundamental Investments's PHAS Position: Q2 2021 in Review

Susquehanna Fundamental Investments sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q2 2021, closing a stake of 15,232 shares — an estimated $53K sold.

Susquehanna Fundamental Investments first reported a position in PHAS in Q3 2020 and held it in 3 quarters. The position peaked at $206K in Q3 2020. 55 funds tracked by Wall St. Rank hold PHAS as of Q2 2021.

  • Susquehanna Fundamental Investments reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 15,232 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q2 2021, an estimated $53K.
  • Susquehanna Fundamental Investments first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q3 2020 and held it in 3 quarters.
  • Susquehanna Fundamental Investments's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $206K in Q3 2020.
  • 55 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q2 2021.

Based on Susquehanna Fundamental Investments's 13F filing for Q2 2021, filed 11 Aug 2021.